Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure extending the disclosure postponement period from December 31, 2025, to December 31, 2031, at the customer’s request regarding the contract manufacturing agreement with UCB originally disclosed on May 17, 2019.
📊 [Key Disclosure Details & Financial Figures]
- Original Filing & Submission Date: Single Sales and Supply Contract (Submitted on May 17, 2019)
- Reason for Correction: Extension of disclosure postponement period at the customer’s request
- Key Correction Items:
- Disclosure Postponement Period: (Before) December 31, 2025 → (After) December 31, 2031
- Contract Overview (Based on Original Filing):
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 40,250,652,017 (USD 33,829,763 / Confirmed revenue through 2021, applied exchange rate KRW 1,189.80 per USD)
- Recent Annual Revenue: KRW 535,805,801,067 (Based on FY2018 financial statements)
- Contract Amount to Revenue Ratio: 7.51%
- Counterparty: UCB
- Contract Date: May 17, 2019
- Other Important Investment Details:
- If the customer succeeds in developing the contracted product, the confirmed minimum guaranteed contract amount will increase to USD 147,656,263, with potential further increases upon mutual agreement if customer demand grows.
- The contract period will be disclosed after December 31, 2031, due to business confidentiality.
- Contract end date and contract amount are subject to change upon mutual agreement.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Disclosure Timeline and Changes Following Postponement Extension
This correction disclosure extends the confidentiality postponement period for the contract manufacturing deal with UCB by six years to December 31, 2031.
Checking the adjusted disclosure timeline and potential contract amount updates is crucial for understanding the ongoing structure and progress of the contract.
Relevant developments can be verified upon the expiration of the extended postponement period (December 31, 2031) or through subsequent correction disclosures and periodic reports.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
